Related Experiment Video
Updated: Jul 3, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease
Uzma A Chaudhry1, Hean Zhuang, Barbara J Crain
1Department of Anesthesiology/Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Summary
Microsomal prostaglandin-E synthase-1 (mPGES-1) is upregulated in Alzheimer's disease (AD) brains. This enzyme is expressed in brain cells, suggesting its role in AD pathogenesis.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Prostaglandin E2 (PGE2) levels fluctuate in Alzheimer's disease (AD) cerebrospinal fluid.
- Cerebral distribution and expression of mPGES-1 in AD brains remain uncharacterized compared to normal brains.
Purpose of the Study:
- To compare the cerebral distribution and expression patterns of mPGES-1 in Alzheimer's disease (AD) and normal human brains.
- Investigate the cellular localization of mPGES-1 in different brain cell types.
Main Methods:
- Western blot analysis of middle frontal gyrus tissue from AD and control brains.
- Immunofluorescence and immunohistochemistry using mPGES-1 specific antibodies.
- Analysis of mPGES-1 expression in neurons, microglia, astrocytes, and endothelial cells.
Main Results:
- Western blotting showed significantly elevated mPGES-1 expression in AD brain tissue.
- Immunofluorescence confirmed mPGES-1 presence in neurons, microglia, and endothelial cells in both control and AD tissue.
- Immunohistochemistry indicated elevated mPGES-1 in pyramidal neurons of AD brains and differential expression in astrocytes.
Conclusions:
- Microsomal prostaglandin-E synthase-1 (mPGES-1) is constitutively expressed in human neurons, microglia, astrocytes, and endothelial cells.
- mPGES-1 expression is upregulated in the context of Alzheimer's disease (AD).
- These findings suggest a role for mPGES-1 in AD pathophysiology.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...